MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Biodesix Long-Term Debt 2011-2025 | BDSX
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Biodesix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40 M | 25.2 M | 5.25 M | - | 15.9 M | 23.8 M | 23.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 40 M | 5.25 M | 22.2 M |
Quarterly Long-Term Debt Biodesix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50 M | 50 M | 40 M | 24.8 M | 40 M | 40.1 M | 40.1 M | 25.2 M | 30.1 M | 30.1 M | 30.1 M | 5.25 M | 21.5 M | - | 10.2 M | 10.1 M | 30.1 M | 33.2 M | 33.1 M | 28.1 M | 24.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 50 M | 5.25 M | 29.8 M |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brainsway Ltd.
BWAY
|
2.08 M | $ 17.13 | 1.66 % | $ 99.4 M |  Israel |
|
Centogene N.V.
CNTG
|
15.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
DarioHealth Corp.
DRIO
|
24.6 M | $ 12.15 | 2.14 % | $ 345 M | Israel |
 |
DexCom
DXCM
|
58.6 M | $ 66.06 | -1.34 % | $ 25.5 B |  USA |
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
13.2 M | $ 101.57 | 0.07 % | $ 18.8 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
18.3 M | $ 16.0 | 1.59 % | $ 172 M |  China |
 |
Accelerate Diagnostics
AXDX
|
782 K | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
3.54 M | $ 1.56 | -3.7 % | $ 1.98 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
9.74 M | $ 38.95 | 0.82 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
15.5 B | $ 227.29 | 0.42 % | $ 166 B | USA |
 |
Fulgent Genetics
FLGT
|
360 K | $ 26.94 | -0.74 % | $ 815 M | USA |
 |
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M | China |
 |
Mettler-Toledo International
MTD
|
1.83 B | $ 1 408.65 | 1.08 % | $ 29.9 B |  Schweiz |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
388 K | - | - | $ 7.1 B |  Australia |
 |
NeoGenomics
NEO
|
340 M | $ 12.15 | 2.53 % | $ 1.54 B | USA |
 |
Neogen Corporation
NEOG
|
875 M | $ 6.84 | -0.36 % | $ 1.48 B | USA |
 |
Genetron Holdings Limited
GTH
|
5.49 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.16 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
28.3 M | $ 19.9 | -3.21 % | $ 1.07 B | USA |
 |
Pacific Biosciences of California
PACB
|
31.6 M | $ 2.12 | - | $ 538 M | USA |
 |
Celcuity
CELC
|
105 M | $ 101.74 | -3.33 % | $ 4.01 B | USA |
 |
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
203 K | $ 3.35 | -6.42 % | $ 107 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
5.7 B | $ 26.46 | -0.62 % | $ 20 B |  Niderland |
 |
Co-Diagnostics
CODX
|
2.15 M | $ 0.3 | -13.39 % | $ 8.8 M | USA |
 |
Precipio
PRPO
|
106 K | $ 24.67 | -1.2 % | $ 32 M | USA |
 |
Quidel Corporation
QDEL
|
101 M | $ 28.82 | 0.07 % | $ 1.21 B | USA |
 |
IQVIA Holdings
IQV
|
12.8 B | $ 224.13 | 0.84 % | $ 40.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.34 B | $ 45.14 | -0.21 % | $ 10 B | Niderland |
 |
Guardant Health
GH
|
1.14 B | $ 103.55 | 1.45 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
2.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
Sotera Health Company
SHC
|
2.21 B | $ 16.76 | -0.42 % | $ 4.74 B | USA |
 |
Soleno Therapeutics
SLNO
|
49.8 M | $ 49.79 | -4.25 % | $ 2 B | USA |
 |
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
546 K | - | -20.0 % | $ 1.06 M | USA |
 |
Thermo Fisher Scientific
TMO
|
31.1 B | $ 574.27 | 0.46 % | $ 219 B | USA |
 |
Illumina
ILMN
|
554 M | $ 134.66 | -0.16 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
2.24 B | $ 197.59 | 2.36 % | $ 10.2 B | USA |
 |
Trinity Biotech plc
TRIB
|
82.7 M | $ 0.96 | -10.6 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
61.8 M | $ 31.39 | 1.47 % | $ 1.88 B | USA |
 |
Quotient Limited
QTNT
|
145 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
5.62 B | $ 184.04 | 0.81 % | $ 20.4 B | USA |
 |
Myriad Genetics
MYGN
|
39.6 M | $ 7.07 | -2.01 % | $ 641 M | USA |